3 VAN DE GRAAFF DRIVE, BURLINGTON, MA
Reports Second Quarter 2026 Financial Results and Business Updates
Investor Presentation
Fractyl Health, Inc. 2026 Annual Meeting Results and Director Elections
Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
Reports First Quarter 2026 Financial Results and Business Updates
Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
Annual Report to Security Holders
Earnings Release
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
SEC Staff Correspondence
Correspondence